DOC logo

Healthpeak Properties

DOC · What the business does, what can go wrong, and how options sellers approach it

What it does

Healthpeak Properties is a real estate investment trust (REIT) that owns healthcare-related real estate in the United States. Its portfolio is concentrated in outpatient medical office buildings and life science space, such as laboratory and research buildings leased to biotech and pharmaceutical tenants. It also has smaller exposure to senior housing and other care-related properties.

How it makes money

Healthpeak earns rent from tenants who lease its buildings. Many leases include scheduled rent increases, and tenants often pay some or all property operating costs. It also earns income from senior housing operations in some structures, where results depend on occupancy and operating costs. It grows by acquiring, developing, and redeveloping properties, and by recycling capital through sales.

Why investors own it

Investors often look at REITs for dividend income and exposure to real assets. Healthpeak offers a way to own healthcare real estate without buying buildings directly. Demand for medical space is tied to long-term trends such as an aging population and ongoing biomedical research. Dividends are not guaranteed and can change.

What can go wrong

  • Life science demand can weaken if biotech funding slows, leading to vacancies and softer rents.
  • Rising interest rates raise borrowing costs and can pressure REIT valuations.
  • Tenants in healthcare can face financial stress, reimbursement changes, or consolidation.
  • Development projects can run late, cost more, or lease up slowly.
  • Senior housing results can swing with labor costs and occupancy.

What to watch

  • Occupancy rates by segment
  • Same-store cash net operating income growth
  • Leasing activity and rent spreads on new and renewed leases
  • Funds from operations (FFO) and the dividend payout relative to it
  • Debt levels, maturities, and interest costs
  • Development pipeline progress
  • Biotech funding conditions
  • Interest rate moves

Options income angle

Options on DOC are generally available across several expirations, though liquidity is usually better in near-dated, at-the-money contracts than in far-dated or deep out-of-the-money strikes. Bid-ask spreads can be wider than on the largest stocks, so check them before trading.

Implied volatility tends to be driven by interest rate expectations, broader REIT sector moves, and earnings dates. Sentiment about life science demand can also play a role.

One caution for premium sellers: a covered call caps upside while leaving downside exposure, and a short put can be assigned during a sharp rate-driven REIT selloff. Also be aware of ex-dividend dates, since early assignment on short calls can happen just before them.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Healthpeak is a healthcare real estate company with outpatient medical, lab and senior housing properties. Its 2025 net income applicable to common shares fell to $70,513 thousand from $242,384 thousand, mainly because of impairment charges on lab joint ventures, while funds from operations rose. The filing also flags softer lab occupancy and a pending public offering of its senior housing business, Janus Living.

How the business did

  • Profit: Net income applicable to common shares was $70,513 thousand versus $242,384 thousand. The filing cites other-than-temporary impairment charges on certain lab unconsolidated joint ventures, fewer gains on real estate sales, and higher interest expense.
  • FFO: Nareit FFO applicable to common shares rose to $1,268,981 thousand from $1,092,730 thousand. FFO (funds from operations) is a REIT earnings measure that adds back real estate depreciation and excludes property sale gains and impairments. FFO as Adjusted was $1,292,256 thousand versus $1,231,868 thousand.
  • Segments: Same-store Adjusted NOI (property-level operating income for a consistent set of buildings) rose 3.8 % in outpatient medical, 1.5 % in lab and 12.6 % in senior housing. Lab same-store end of period occupancy was 90.1 % versus 97.8 % a year earlier. Senior housing same-store average occupancy was 86.6 % versus 85.4 %.
  • Cash and capital return: Net cash provided by operating activities was $1,251,959 thousand versus $1,070,497 thousand. Common dividends totaled $1.22 per share, paid monthly since April 2025. The company repurchased 5.09 million shares for $94 million.

Risks specific to this company

  • Lab tenant funding: Lab tenants depend on investor money and NIH grants. The filing says federal policy changes, tariffs and drug pricing uncertainty have hurt, and could keep hurting, their ability to raise capital and pay rent.
  • Geographic concentration: Approximately 69% of the lab portfolio is in California (earthquake and wildfire exposure). Approximately 69% of the life plan community portfolio is in Florida (hurricane exposure). Insurance may not cover all losses.
  • Debt: Outstanding indebtedness was approximately $9.8 billion. Within twelve months, $650 million of senior unsecured notes and $345 million of mortgage debt come due. Fixed rate debt fell to approximately 88% from 97%.
  • Healthcare reimbursement: Medicaid cuts and expired Affordable Care Act subsidies could weaken tenants, operators and borrowers. Facilities in states that did not expand Medicaid face higher risk.
  • Senior housing operating risk: Under RIDEA, a structure where the company's taxable subsidiary owns the operating business and an operator runs it day to day, the company carries the operating and legal liabilities. Its indemnification rights against operators are limited.
  • Janus Living Offering: It may be delayed, may cost more than expected, or may not happen. If completed, the company will hold a majority stake, with conflicts of interest between the two companies.

What management is watching

  • Janus Living Offering: Management expects it to complete in the first half of 2026, with Healthpeak managing Janus Living and retaining a substantial majority equity interest.
  • Macro and policy: Management points to inflation, interest rates, capital availability for life science companies, tariffs and healthcare policy as the main uncertainties. It says higher construction costs and tariffs have hurt construction starts and expected yields on projects.
  • Spending and deals: In January 2026 the company bought the remaining 50% of the Gateway Crossing JV for $132 million and the remaining 46.5% of the SWF SH JV for $312 million. It also repaid $103 million of mortgage debt early. Development and redevelopment commitments were $168 million, with $134 million expected within twelve months.
  • Dividends: The board declared a monthly dividend of $0.10167 per share for January through March 2026.
  • Measures: Management directs investors to Adjusted NOI, Nareit FFO, FFO as Adjusted and AFFO (FFO as Adjusted after recurring capital spending and other adjustments). AFFO applicable to common shares was $1,183,568 thousand.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Healthpeak reported net income applicable to common shares of $17,118 thousand for the quarter ended September 30, 2026, against a loss of $117,256 thousand a year earlier. The swing came mostly from the absence of last year's impairment charges, not from stronger property income. Funds from operations (FFO), a REIT earnings measure that adds back real estate depreciation, fell, as the company's mix moved toward senior housing and weakened in lab.

How the business did

  • Quarter results: Nareit FFO applicable to common shares was $296,789 thousand versus $318,155 thousand a year earlier. FFO as Adjusted, which also strips out one-time items, was $304,888 thousand versus $318,750 thousand. For the nine months, net income was $263,270 thousand versus a loss of $43,335 thousand, while FFO as Adjusted was $938,269 thousand versus $965,087 thousand.
  • Segments: Same-Store Adjusted NOI (property income after property-level costs, for buildings owned throughout both periods) rose 3.1% in outpatient medical and 25.9% in senior housing. It fell (0.7)% in lab, where same-store end-of-period occupancy was 90.6% versus 92.7%. Total-portfolio lab end-of-period occupancy was 85.9% versus 93.4%.
  • Cost pressure: Depreciation, interest expense, general and administrative costs (including stand-alone costs for Janus Living) and transaction costs all rose.
  • Cash flow: Net cash from operating activities for the nine months was $976,440 thousand versus $957,875 thousand. Investing used $2,578,978 thousand, mainly for acquisitions.
  • Capital moves: Janus Living, the senior housing company, completed its IPO in March 2026 and two follow-on offerings. The company holds 69.2% of it. In July 2026 the company formed a joint venture with Brookfield covering 86 outpatient medical buildings at a gross valuation of approximately $2.1 billion. It repaid $650 million of 3.25% senior unsecured notes, and repurchased shares for $100 million earlier in the year.

What management is watching

  • Rates and costs: Management points to an increase in the target federal funds rate in September 2026, persistent inflation, and tariff and construction cost pressure that have hurt construction starts and expected returns on development projects. Fixed rate debt was approximately 83% of consolidated debt, versus 95% a year earlier.
  • Funding and liquidity: The company expects cash flow, cash on hand and financing to cover the next 12 months. It amended the Janus Living credit facilities to a $1.25 billion revolving commitment and added a $500 million four-year delayed draw term loan in October 2026, with nothing drawn as of November 3, 2026.
  • Investment plans: After quarter-end it completed $432 million of senior housing acquisitions. A new $500 million share repurchase program was approved in July 2026, with no shares bought under it yet. The monthly dividend stayed at $0.10167 per share.
  • Measures cited: Management directs investors to Adjusted NOI, Same-Store results, Nareit FFO and FFO as Adjusted. This section gives no full-year earnings targets.

Follow DOC in Kortex

The Kortex app shows DOC's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.